Culture

 

British Queen celebrates

image image image image
Starmer government places international law at core of foreign policy, says Attorney General Read the Full Story
Chief Rabbi and Ex-MP Louise Ellman among 63 Brits evacuated from Israel by RAF Read the Full Story
UK to boost defence spending to 5% of GDP by 2035, says Starmer Read the Full Story
UK commits £1 billion to new biosecurity centre to guard against future pandemics Read the Full Story
* * * *

UK News

World News

Media

 

Following approval from the British health regulator for Eli Lilly's new weight-loss treatment, Health Secretary Steve Barclay expressed optimism about the potential benefits for thousands of

obese individuals in the UK. The drug, Zepbound (also known as Mounjaro or tirzepatide), received the green light from both U.S. and UK regulators, offering a formidable competitor to Novo Nordisk's Wegovy in addressing rising obesity rates.

In a statement, Barclay highlighted the drug's potential to assist people struggling with obesity and alleviate weight-related health issues when combined with proper diet and physical activity. He emphasized the impact on reducing waiting lists and potential cost savings for the National Health Service (NHS).

However, Barclay noted that additional approvals were necessary before the drug could be included in NHS coverage.